Search
Support us

Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer.

  • Show more authors
    + 16
  • N de Gruil
  • A F de Groot
  • Y Wesseling-Rozendaal
  • D Keizer
  • C S Koekenbier
  • S Vermeer
  • D Cohen
  • J B Heijns
  • C M P W Mandigers
  • A J van de Wouw
  • M Cloos-van Balen
  • J A Ropela
  • H M Oosterkamp
  • M L van Bekkum
  • D Houtsma
  • E den Biezen
  • G J Liefers
  • S C Linn
  • J R Kroep

More about this publication

Breast cancer research : BCR
  • Publication date 25-02-2026
Full text links

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.